Skip to main content
TNYA
NASDAQ Life Sciences

Tenaya Seeks Stockholder Approval for 1-for-10 to 1-for-25 Reverse Split to Avoid Nasdaq Delisting

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$0.53
Mkt Cap
$116.824M
52W Low
$0.517
52W High
$2.2
52W Position info
2.5% above low
Off High info
76% below high
Rel. Volume info
1.1× avg
Market data snapshot near publication time

TNYA is trading near its 52-week low of $0.517 (2.5% above the low).

Summary

Tenaya Therapeutics filed a preliminary proxy seeking approval for a reverse stock split between 1-for-10 and 1-for-25 to regain Nasdaq's $1.00 minimum bid price requirement. The special meeting is set for December 9, 2026, with the compliance deadline on January 25, 2027.


Key Events · Corporate Governance and Compliance · TNYA

  • Reverse Stock Split Proposal

    Board seeks approval to effect a reverse split at a ratio between 1-for-10 and 1-for-25, with the exact ratio determined by the board at its discretion.

  • Nasdaq Delisting Risk

    Company received a delisting notice in January 2026 for trading below $1.00. After transferring to Nasdaq Capital Market, the compliance deadline is January 25, 2027.

  • Special Meeting Scheduled

    Stockholders will vote on the reverse split proposal at a virtual special meeting on December 9, 2026. Record date is October 19, 2026.

  • Share Count Impact

    At a 1-for-10 ratio, outstanding shares would drop from 227.9M to 22.8M; at 1-for-25, to 9.1M. Authorized shares remain unchanged at 1.0B.


Analysis · TNYA · Life Sciences

Tenaya Therapeutics is asking stockholders to approve a reverse stock split at a ratio between 1-for-10 and 1-for-25. The company received a Nasdaq delisting notice in January 2026 because its stock traded below $1.00 for 30 consecutive business days. After transferring to the Nasdaq Capital Market, the compliance deadline is January 25, 2027. With the stock at $0.53 and near its 52-week low, the reverse split is the primary tool to regain the $1.00 minimum bid price. The board has discretion to choose the exact ratio and to abandon the split entirely. If the split fails to lift the price, delisting to the OTC market would reduce liquidity, limit institutional ownership, and make future capital raises more difficult.

How filings like this one have moved

In the 30 days to Nov 11, 2026, 48.1% of the 1752 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.29%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, TNYA was trading at $0.53 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $116.8M. The 52-week trading range was $0.52 to $2.20. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

TNYA - Latest Insights

TNYA
Nov 04, 2026, 4:41 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $0.377
Real-time Price: $0.3783 info
Change: +$0.0013 (+0.34%) info
Market Cap: $84.607M info
TNYA
Nov 04, 2026, 4:13 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.385
Real-time Price: $0.3783 info
Change: -$0.0067 (-2%) info
Market Cap: $84.607M info
TNYA
Sep 14, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $0.6395
Real-time Price: $0.3783 info
Change: -$0.2612 (-41%) info
Market Cap: $84.607M info
TNYA
Aug 05, 2026, 4:46 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $0.7497
Real-time Price: $0.3783 info
Change: -$0.3714 (-50%) info
Market Cap: $84.607M info
TNYA
Jul 02, 2026, 5:00 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.7865
Real-time Price: $0.3783 info
Change: -$0.4082 (-52%) info
Market Cap: $84.607M info